ERBB2 and neoplasm: We previously reported that 20–30% of neu-N mice treated with this vaccine and immune modulating doses of cyclophosphamide (Cy) to deplete Tregs develop high avidity RNEU420–429-specific CTL responses that are associated with tumor clearance.